Fifth Third Bancorp Takes $279,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Fifth Third Bancorp bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 6,560 shares of the company's stock, valued at approximately $279,000.

Several other institutional investors have also added to or reduced their stakes in GH. Vanguard Group Inc. grew its stake in shares of Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after acquiring an additional 350,606 shares during the period. Deep Track Capital LP boosted its holdings in Guardant Health by 7.0% in the fourth quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock worth $196,118,000 after purchasing an additional 419,006 shares during the last quarter. Two Sigma Advisers LP grew its position in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock worth $70,742,000 after purchasing an additional 1,138,300 shares during the period. Two Sigma Investments LP raised its stake in Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after buying an additional 525,368 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. raised its stake in Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after buying an additional 197,729 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Price Performance

NASDAQ:GH opened at $50.57 on Thursday. The company has a market cap of $6.27 billion, a price-to-earnings ratio of -14.92 and a beta of 1.37. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92. The stock's 50 day simple moving average is $44.16 and its two-hundred day simple moving average is $41.86.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 53.82% and a negative return on equity of 1,200.44%. The company had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. Guardant Health's revenue was up 20.8% on a year-over-year basis. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Transactions at Guardant Health

In other news, Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction on Monday, June 16th. The stock was sold at an average price of $49.70, for a total transaction of $130,512.20. Following the completion of the sale, the director now directly owns 18,180 shares in the company, valued at approximately $903,546. This trade represents a 12.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Meghan V. Joyce sold 3,337 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $47.22, for a total transaction of $157,573.14. Following the transaction, the director now directly owns 11,150 shares in the company, valued at approximately $526,503. This trade represents a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 232,363 shares of company stock worth $11,509,565. 6.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Scotiabank restated an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Mizuho upped their target price on shares of Guardant Health from $60.00 to $65.00 and gave the company an "outperform" rating in a report on Friday, June 13th. Morgan Stanley boosted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Stephens reaffirmed an "overweight" rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Finally, Guggenheim reiterated a "buy" rating and set a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Twenty-one research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $53.76.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.